NASDAQ : SLNO
Soleno Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 53.01 USD (At close: May 15, 2026) · Market cap 2.76B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.76B |
| Enterprise Value | 2.29B |
Dates
| Measure | Value |
|---|
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 52.12M |
| Shares Outstanding | 52.12M |
| Shares Change (YoY) | +26.81% |
| Shares Change (QoQ) | -2.33% |
| Owned by Insiders (%) | 1.28% |
| Owned by Institutions (%) | 100.49% |
| Float | 51.45M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 30.00 |
| Forward PE | 11.16 |
| PS Ratio | 9.69 |
| Forward PS | 5.13 |
| PB Ratio | 5.53 |
| P/TBV Ratio | 5.62 |
| P/FCF Ratio | 26.21 |
| P/OCF Ratio | 26.18 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 23.93 |
| EV / Sales | 8.03 |
| EV / EBITDA | 25.00 |
| EV / EBIT | 25.57 |
| EV / FCF | 21.71 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.62 |
| Quick Ratio | 5.22 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.59 |
| Debt / FCF | 0.51 |
| Interest Coverage | 16.55 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 26.38% |
| Return on Assets (ROA) | 12.07% |
| Return on Invested Capital (ROIC) | 35.11% |
| Return on Capital Employed (ROCE) | 16.26% |
| Weighted Average Cost of Capital (WACC) | -7.60% |
| Revenue Per Employee | $1.57M |
| Profits Per Employee | $525,418 |
| Employee Count | 182 |
| Asset Turnover | 0.62 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 3.54M |
| Effective Tax Rate | 3.55% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -2.22 |
| 52-Week Price Change | -27.84% |
| 50-Day Moving Average | 45.52 |
| 200-Day Moving Average | 52.56 |
| Relative Strength Index (RSI) | 77.67 |
| Average Volume (20 Days) | 1,909,190 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.53M |
| Short Previous Month | 5.80M |
| Short % of Shares Out | 12.52% |
| Short % of Float | 12.68% |
| Short Ratio (days to cover) | 1.01 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 285.01M |
| Gross Profit | 281.11M |
| Operating Income | 89.49M |
| Pretax Income | 99.58M |
| Net Income | 95.63M |
| EBITDA | 91.52M |
| EBIT | 89.49M |
| Earnings Per Share (EPS) | $1.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 255.60M |
| Total Debt | 54.28M |
| Net Cash | 474.70M |
| Net Cash Per Share | $9.11 |
| Equity (Book Value) | 495.80M |
| Book Value Per Share | 9.59 |
| Working Capital | 268.33M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 105.53M |
| Capital Expenditures | -108,000 |
| Depreciation & Amortization | 2.03M |
| Net Borrowing | n/a |
| Free Cash Flow | 105.42M |
| FCF Per Share | $2.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | 98.63% |
| Operating Margin | 31.40% |
| Pretax Margin | 34.94% |
| Profit Margin | 33.70% |
| EBITDA Margin | 32.11% |
| EBIT Margin | 31.40% |
| FCF Margin | 36.99% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.81% |
| Shareholder Yield | -26.81% |
| Earnings Yield | 3.46% |
| FCF Yield | 3.82% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $53.00 |
| Price Target Difference | -0.02% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 26, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 17.41 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |